Skip to contentpdufa.bio

ALN-2232 Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

ALN-2232 Phase is an Alnylam Pharmaceuticals, Inc. program in obesity and weight management. Its next catalyst is a Readout in Feb 2027.

ALNY catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Obesity and weight management. Sponsor: Alnylam Pharmaceuticals, Inc. (ALNY). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Feb 2027ALNY

Questions

When is ALN-2232 Phase's next FDA decision or readout?

The next tracked catalyst for ALN-2232 Phase is a Readout in Feb 2027.

What happened at ALN-2232 Phase's most recent FDA decision?

No FDA decision for ALN-2232 Phase is in our archive yet.

What is ALN-2232 Phase used for?

In our records ALN-2232 Phase is under review or in development for Obesity and weight management.

Who makes ALN-2232 Phase?

Alnylam Pharmaceuticals, Inc. (ALNY).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.